Follow The Filings

ICCC ImmuCell

ImmuCell earnings company data as of 4:48 AM ET 10/23

History

2 periods, newest first. Each row shows EPS above revenue.

Period Date Metric Estimate Actual Result
FY2026 Q3 12 Nov EPS — — —
Rev — — —
FY2026 Q2 13 Aug EPS — 0.20 —
Rev — — —

Insider trades

Open-market buys and sales by ICCC's executives, directors and 10% owners in the last 12 months, from their Form 4s

All ICCC insider trades
  • $141K bought by 2 insiders
  • None no sales outside a trading plan
  • None no planned (10b5-1) sales
  1. Boekhorst Paul Francis Olivier Te CEO
    Buy
    $76K 8,000 shares at $9.50 +82% to stake
    Traded Jun 18 Filed Jun 22
    ↗
  2. Boekhorst Paul Francis Olivier Te CEO
    Buy
    $32K 6,030 shares at $5.23 +163% to stake
    Traded Dec 3–4 Filed Dec 4, 2025
    ↗
  3. Boekhorst Paul Francis Olivier Te CEO
    Buy
    $18K 3,708 shares at $4.87 New stake
    Traded Dec 2, 2025 Filed Dec 3, 2025
    ↗
  4. David Scott Tomsche Director
    Buy
    $16K 3,266 shares at $4.76
    Traded Nov 25, 2025 Filed Nov 28, 2025
    ↗

Also filed in the last 12 months, not counted as buying or selling: 1 share withholding for taxes and 1 option exercise.

SEC filings

Recent issuer filings from EDGAR, 21 shown.

Filed Form Detail Links
8-K 2.02,9.01 Filing Doc
8-K 2.02,9.01 Filing Doc
10-Q FORM 10-Q Filing Doc
8-K 2.02,9.01 Filing Doc
8-K 5.07,9.01 Filing Doc
8-K 7.01,9.01 Filing Doc
10-Q FORM 10-Q Filing Doc
8-K 2.02,9.01 Filing Doc
10-K/A FORM 10-K/A Filing Doc
8-K 1.01 Filing Doc
DEF 14A FORM DEF 14A Filing Doc
8-K 5.02,8.01,9.01 Filing Doc
8-K 2.02,9.01 Filing Doc
10-K FORM 10-K Filing Doc
8-K 5.02,9.01 Filing Doc
8-K 2.02,9.01 Filing Doc
8-K 5.02,9.01 Filing Doc
8-K 1.01,5.02,9.01 Filing Doc
8-K 2.02,2.06,8.01,9.01 Filing Doc
8-K 2.06,8.01,9.01 Filing Doc
SCHEDULE 13D/A — Filing Doc

Source: SEC EDGAR submissions, updated 5 days ago. All on EDGAR

Estimates are consensus figures; SEC filings remain the official record. Not investment advice.